Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis

Sachiko Hattori (✉ sh07172017@olive.plala.or.jp)  
Tohto Clinic  https://orcid.org/0000-0002-4580-4382

Kazuhiro Nomoto  
Tohto Clinic

Tomohiko Suzuki  
Ohkubo Hospital

Seishu Hayashi  
Ohkubo Hospital

Short report

Keywords: NAFLD/NASH, Oramigliptin, Dipeptidyl peptidase 4

Posted Date: December 16th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-128674/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License

Version of Record: A version of this preprint was published on March 10th, 2021. See the published version at https://doi.org/10.1186/s13098-021-00644-5.
Abstract

Background: Dipeptidyl peptidase 4 (DPP4) is a serine exopeptidase able to inactivate various oligopeptides and also a hepatokine. Hepatocyte-specific overexpression of DPP4 is associated with hepatic insulin resistance and liver steatosis.

Method: We examined whether weekly DPP4 inhibitor omarigliptin (OMG) improves liver function as well as levels of inflammation and insulin resistance in type 2 diabetic patients with non-alcoholic fatty liver disease (NAFLD). Furthermore, we tried OMG in a diabetic patient with biopsy-confirmed nonalcoholic steatohepatitis (NASH).

Results: In NAFLD patients, OMG significantly decreased levels of aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (gGTP), homeostatic model assessment of insulin resistance (HOMA-IR), and high-sensitivity C-reactive protein (hsCRP), while no significant change was seen in hemoglobin A1c (HbA1c) or body mass index (BMI). In a NASH patient, liver function had improved markedly, and the hepatic fibrosis marker FIB-4 decreased in parallel with HOMA-IR and hsCRP. Improvements in intrahepatic fat deposition and fibrosis appeared to be seen on ultrasonography.

Conclusion: The effects of OMG in ameliorating hepatic insulin resistance may lead to decreasing intrahepatic fat accumulation and improving intrahepatic adipose inflammation in NAFLD/NASH.


Background

Dipeptidyl peptidase 4 (DPP4) is a serine exopeptidase able to inactivate various oligopeptides through the removal of N-terminal dipeptides [1]. The activity of DPP4 seems to be increased in patients with type 2 diabetes, and various in vitro and in vivo studies have demonstrated that this enzyme can interact with proinflammatory pathways[1]. DPP4 is also a hepatokine [2], and levels of this enzyme have thus been seen to be elevated in chronic liver diseases including hepatitis C, hepatitis B, non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma.

A direct association exists between DPP4 activity and insulin resistance in humans [3]. Evidence suggests that obesity in mice stimulates hepatocytes to synthesize and secrete DPP4, in turn promoting inflammation of adipose tissue macrophages and insulin resistance. Interestingly, silencing expression of DPP4 on hepatocytes suppressed inflammation of visceral adipose tissue and insulin resistance, but this effect did not occur with sitagliptin, an orally administered DPP4 inhibitor [4].

We recently reported that omarigliptin (OMG), a potent, selective, DPP4 inhibitor with a half-life that allows weekly dosing, decreased inflammation and insulin resistance without affecting hemoglobin A1c
(HbA1c) or body mass index (BMI) in patients with type 2 diabetes, but daily DPP4 inhibitors such as sitagliptin did not change levels of inflammation and insulin resistance [5].

Since hepatic expression of DPP4 is associated with NAFLD [6], we examined whether OMG improves liver function as well as levels of inflammation and insulin resistance in type 2 diabetic patients with NAFLD. Furthermore, we tried OMG in a diabetic patient with biopsy-confirmed nonalcoholic steatohepatitis (NASH).

**Method**

**Study design**

This prospective study included a total of 84 patients with HbA1c > 6.0% regardless of diet, exercise, and medical treatment with the DPP4 inhibitors sitagliptin (50 mg/day) or linagliptin (5 mg/day) for ≥ 12 months in this clinic. Patients were allocated in a 1:2 ratio using numbered containers to continue with the same daily regimen of sitagliptin 50 mg/day (n = 19) or linagliptin 5 mg/day (n = 9) as a control group (n = 28) or to switch from sitagliptin (n = 40) or linagliptin (n = 16) to OMG 25 mg/week (OMG group: n = 56). In each group, NAFLD was retrospectively diagnosed by ultrasonography performed at enrollment for 12 patients in the control group and 21 patients in the OMG group. In these NAFLD patients, changes from baseline to 1 year for HbA1c, BMI, Homeostatic model assessment of insulin resistance (HOMA-IR), high-sensitivity C-reactive protein (hsCRP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transpeptidase (gGTP) were evaluated. Furthermore, we tried OMG in a patient with biopsy-confirmed NASH. This patient was a 73-year-old man who was found to have fatty liver on abdominal ultrasonography at about 35 years old. Type 2 diabetes and dyslipidemia were then found at about 40 years old, and he began therapy at about 50 years old. He did not modify his lifestyle habits in any particular manner and continued to eat a high-fat, high-salt diet and smoke (20 cigarettes/day for 50 years), but not drink alcohol. We measured HbA1c, BMI, HOMA-IR, hsCRP, liver function, and hepatic fibrosis markers in this patient, and results of ultrasonography were tracked over time.

**Criteria for NAFLD diagnosis**

NAFLD was diagnosed by ultrasonography according to the presence of one of the following criteria: i) bright homogeneous echoes in the liver parenchyma; ii) hepatorenal echogenicity contrast (+); iii) hepatosplenic echogenicity contrast (+); iv) echoes with deep attenuation in the liver parenchyma; or v) impaired visualization of the peripheral portal and hepatic veins. Exclusion criteria were a history of hepatic diseases, such as hepatitis C, hepatitis B, or primary biliary cirrhosis, or a history with past consumption of alcohol > 20 g/day.

**Statistical analysis**
Paired t-tests were used to compare parameters before treatment and at 12 months after treatment. Differences were considered statistically significant at the level of $p < 0.05$.

**Results**

**Effect of OMG in diabetic patients with NAFLD**

No significant differences were seen in any parameters in the control group. In the OMG group, significant differences were observed in ALT, AST, gGTP, HOMA-IR, and hsCRP, while no significant differences were seen in HbA1c or BMI (Table 1).

**Effect of OMG in a diabetic patient with NASH**

This patient was referred to our department at 64 years old for worsened liver function and poor glycemic control. The results of physical examination at the initial consultation were as follows: height, 182 cm; weight, 74.1 kg; BMI, 22.37 kg/m²; blood pressure, 128/80 mmHg; heart rate, 78 beats/min and regular; no anemia or jaundice; electrocardiography and chest X-ray, no findings of note; abdominal examination, no subjective symptoms; bilateral patellar and Achilles tendon reflexes, normal; diabetic retinopathy and neuropathy, absent; and diabetic nephropathy stage I (albumin/creatinine ratio, 5.6 mg/g creatinine).

After the initial treatment with glimepiride 2 mg/day and sitagliptin 100 mg/day, laboratory results were: AST, 69 IU/L; ALT, 83 IU/L; fibrosis-4 (FIB-4) index [7], 2.78; Mac-2-binding protein glycosylation isomer (M2BPGi), 1.12; HbA1c, 7.8%; HOMA-IR, 2.61; and hsCRP, 0.054 mg/dL. Pioglitazone was then prescribed at 15 mg/day, with the dose subsequently increased to 30 mg/day. Moreover, after switching from sitagliptin to linagliptin, laboratory results improved as follows: AST, 45 IU/L; ALT, 52 IU/L; HbA1c, 7.2%; and HOMA-IR, 2.1. At 68 years old, laboratory results again worsened: AST, 61 IU/L; ALT, 79 IU/L; FIB-4 index, 2.29; M2BPGi, 1.14; HbA1c, 7.4%; HOMA-IR, 2.19; and hsCRP, 0.048 mg/dL. In response, pioglitazone was switched to metformin 1000 mg/day, which led to an improving trend, with HbA1c at 6.9%, but no changes in liver function or hepatic fibrosis markers. Liver biopsy was then performed, and NASH (Brunt criteria: grade 1, stage 3) was diagnosed, indicating better control of diabetes mellitus as a critical issue. Therapy was switched from linagliptin to OMG, which has wide organ distribution including the liver, is present stably in the body without accumulation, and is safe to use [8]. Twenty-four months later, liver function had improved markedly: AST, 20 IU/L; ALT, 19 IU/L; FIB-4, 1.47; M2BPGi, 0.58; HbA1c, 6.4%; HOMA-IR, 1.26; and hsCRP, 0.028 mg/dL (Table 2). The hepatic fibrosis marker FIB-4 changed in parallel with HOMA-IR and hsCRP (Fig. 1). Thereafter, improvements in intrahepatic fat deposition and fibrosis were seen on ultrasonography.

**Discussion**

NAFLD is primary characterized by the accumulation of intrahepatic tryglycerides (TGs) and is present in 75–90% of subjects with type 2 diabetes [9, 10]. NAFLD may progress to the more severe condition of NASH, characterized by advanced histological remodeling including fibrosis, lobular inflammation,
hepatocellular ballooning, and risk of liver cancer. Since numerous pathways including insulin resistance, lipotoxicity, oxidative stress, immunology, the cytokine system, mitochondrial damage, and apoptosis are involved in the pathophysiology of NASH, various pharmacotherapies are being developed. Although no presently available drugs can be recommended for evidence-based treatment of NASH, antidiabetic drugs may prove useful in patients with comorbid diabetes mellitus.

We found that OMG appears to offer benefits for NAFLD patients along with decreased insulin resistance and inflammation. Based on this experience, we tried OMG on a NASH patient in whom glycemic control, liver function, and hepatic fibrosis markers improved markedly, along with decreased HOMA-IR and hsCRP, and improvements in intrahepatic fat deposition and fibrosis were seen on diagnostic imaging.

DPP4 has been linked to hepatic insulin sensitivity in several studies. Thus, in mice, hepatocyte-specific overexpression of DPP4 is associated with hepatic insulin resistance and liver steatosis [6], whereas knockdown of DPP4 improves insulin sensitivity and reduces lipid accumulation in cultured hepatocytes [11]. Other studies have pointed toward DPP4 acting as a hepatokine, linking the liver and adipose tissue with the development of insulin resistance, and glucose intolerance. In mice, obesity and the associated visceral adipose tissue inflammation result in insulin resistance, a process that appears to be mediated via increased synthesis and release of hepatic DPP4, since eliminating hepatocyte DPP4 expression suppresses inflammation and improves insulin sensitivity [4, 12]. The mechanism seems independent of the catalytic activity of DPP4, since these effects were not mimicked by systemic daily DPP4 inhibition [4, 12]. On the other hand, the inhibition of the catalytic activity of DPP4 with DPP4 inhibitors was suggested to be, at least partially, involved since insulin signaling was improved following inclusion of DPP4 inhibitors in adipocytes in culture, but the DPP4 substrates mediating the effect remained unidentified [13, 14].

The issue of why weekly OMG shows beneficial effects against NAFLD/NASH where daily DPP4 inhibitors do not might be attributable to the concentration of molecules under the condition. The activity of daily DPP4 inhibitors is evaluated by inhibition of the ability of DPP4 serine exopeptidase to inactivate incretins in the blood. The concentration of daily DPP4 inhibitors in organs including the liver thus appears very low while insulin-stimulated activation of Akt is augmented by sitagliptin and saxagliptin in adipocytes in culture where cells are exposed to certain concentrations of DPP4 inhibitors [13, 14]. On the other hand, OMG after single oral administration continues to be detected in the mouse liver for 1 week [8].

DPP4 is proposed to represent a novel adipokine that may impair insulin sensitivity in autocrine and paracrine fashions [13]. DPP4 release strongly correlates with adipocyte size, potentially representing an important source of DPP4 [13]. The greater the fat content in the liver, the greater the expression/secretion of hepatokine DPP4, which might lead to NAFLD, and then to NASH. OMG might thus block the activity of DPP4 highly secreted from the liver under conditions of NAFLD/NASH, averting the promotion of adipose inflammation and insulin resistance in autocrine and paracrine fashions.
Accordingly, excess DPP4 derived from adipocytes and/or hepatocytes may act as a local mediator of inflammation and adipose/hepatic tissue insulin resistance, thereby forming a link between obesity and the pathogenesis of type2 diabetes and metabolic disease. Sodium-glucose transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists have recently shown potential efficacy for the treatment of NAFLD/NASH with diabetes [1, 15, 16], but are expected to be more effective for NAFLD/NASH in obese diabetic patients. The effects of OMG in decreasing intrahepatic fat accumulation and improving intrahepatic adipose inflammation are expected to be helpful for the treatment of NAFLD/NASH, particularly in non-obese, insulin-resistant, diabetic patients.

The limitations of the present study were the relatively small number of participants. Since this is a novel possible therapeutics for NAFLD/NASH complicated with diabetes, long-term assessments of large number of patients would be necessary.

**Conclusion**

Hepatocyte-specific overexpression of DPP4 is associated with hepatic insulin resistance and liver steatosis. The effects of weekly DPP4 inhibitor OMG in ameliorating hepatic insulin resistance may lead to decreasing intrahepatic fat accumulation and improving intrahepatic adipose inflammation in NAFLD/NASH.

**Abbreviations**

ALT, alanine aminotransferase

AST, aspartate aminotransferase

BMI, body mass index

DPP4, dipeptidyl peptidase 4

FIB-4 index, fibrosis-4 index

GLP-1, glucagon-like peptide-1

FBG, fasting blood glucose

HbA1c, hemoglobin A1c

HDL, high-density lipoprotein

HOMA-IR, homeostatic model assessment of insulin resistance

hsCRP, high sensitivity C-reactive protein
M2BPGi, Mac-2 binding protein glycosylation isomer (M2BPGi)

TG, triglyceride

γGTP, gamma-glutamyl transpeptidase

**Declarations**

**Ethics approval and consent to participate**

The study was approved by the ethic committee at the Tohto Clinic, and written informed consent was obtained from all participating patients before the initiation of the study.

**Consent for publication**

All authors participated in drafting this article and gave final approval of the version to be submitted.

**Availability of data and materials**

The datasets analyzed during the current study are not publicly available due to some relevant ongoing studies, but may be available from the corresponding author of this article on reasonable request.

**Competing interests**

There is not a conflict of interest.

**Funding**

This work isn't receiving any funding.

**Authors contributions**

All authors have contributed significantly. Dr. Hattori and Dr. Nomoto made substantial contributions to conception and design, and acquisition of the data. Dr. Suzuki and Dr. Hayashi contributed to acquisition of the data in terms of liver status.

**Acknowledgements**

The authors thank the members of the Tohto Clinic for helping their implement this work plan.

**References**


8. Omarigliptin Pharmaceutical interview form 2016; 4th


Figure 1

Time course of FIB-4 index, HOMA-IR, and hsCRP in a type 2 diabetic patient with NASH. FIB-4: blue squares, HOMA-IR: green triangles, hs CRP: red circles. FIB-4 = age ([yr] x AST [U/L]) / ((PLT [10(9)/L]) x (ALT [U/L])(1/2))
Figure 1

Time course of FIB-4 index, HOMA-IR, and hsCRP in a type 2 diabetic patient with NASH. FIB-4: blue squares, HOMA-IR: green triangles, hs CRP: red circles. FIB-4 = age ([yr] x AST [U/L]) / ((PLT [10(9)/L]) x (ALT [U/L])(1/2))

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Table1.xlsx
- Table1.xlsx
- Table2.xls
- Table2.xls